Creative Biolabs Provides Anti-EGFR Therapeutic Antibody---Nimotuzumab for Research Use

SHIRLEY, NY, USE - Feb 19, 2020 - February 19, 2020, Creative Biolabs, as a leading supplier in the recombinant antibody field, announced that the nimotuzumab, a kind of anti-EGFR therapeutic antibody, is now available for research and clinical use. Depending on cutting-edge hybridoma development and phage display platforms, Creative Biolabs has the ability to offer customers a comprehensive of products and services related to recombinant antibody researches. Since its establishment, Creative Biolabs has offered services for more than one million scientists from different fields, including academic, clinical trail and industry fields. This announcement will be another milestone for Creative Biolabs.

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that consists of an N-terminal extracellular ligand-binding domain and a hydrophobic transmembrane α-helical domain (anchored by It is a member of the HER receptor family. It consists of three parts: tyrosine kinase domain and intracellular tyrosine kinase domain. When EGFR binds to the ligand, the intracellular tyrosine kinase domain will undergo cross-link phosphorylation, which will cause the activation of a series of downstream signaling pathways. EGFR is not only expressed in all epidermal cells and some normal tissue cells of the human body, but also overexpressed in many solid tumors in humans.The expression level of the receptor is closely related to the degree of tumor differentiation, malignancy, tumor invasion and prognosis. Related. Therefore, the treatment of tumors with EGFR as a target has become a new hot spot in tumor treatment, and small molecule chemical drugs and large molecule monoclonal antibodies with EGFR as targets have also appeared on the market, such as human and mouse chimeric antibodies against EGFR Cetuximab.

EGFR is overexpressed in a variety of solid tumors, such as head and neck cancer, lung cancer, and colorectal cancer. EGFR overexpression is highly correlated with tumors' high invasiveness, high metastasis, and poor prognosis. Nitouzumab is the first monoclonal antibody drug targeting epidermal growth factor receptor (EGFR) in the world, and the first humanized monoclonal antibody in China to treat malignant tumors. Nitouzumab can competitively bind EGFR, block EGFR and its downstream signal transduction pathway, thereby inhibit tumor cell proliferation, induce differentiation, promote apoptosis, inhibit tumor angiogenesis, and enhance the efficacy of radiotherapy and chemotherapy.

“with the faith of providing high-quality and professional services and products, scientists from Creative Biolabs has contributed a lot to develop and test items and then put them on the market, so it is guaranteed that products can function well in different researches, and presenting good results to researchers. Nimotuzumab, a humanized monoclonal antibody from Creative Biolabs is only used for research.” said Dr. Conrad, a senior scientist from R&D in Creative Biolabs.

About Creative Biolabs

With more than ten-year experience in providing recombinant antibody services and products, Creative Biolabs enjoyed high praise from its loyal clients from different country. And of course, customers have a great experience in Creative Biolabs. Creative Biolabs is very trustworthy.